<DOC>
	<DOCNO>NCT01543503</DOCNO>
	<brief_summary>This prospective , multi-center , observational study ass efficacy safety treatment patient treat TNF Inhibitor RoActemra/Actemra ( tocilizumab ) first biologic therapy . Data collect 52 week .</brief_summary>
	<brief_title>An Global Comparative Observational Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis rheumatoid arthritis Nonrespondent intolerant nonbiologic diseasemodifying antirheumatic drug ( DMARD ) therapy Patient prescribe first biologic therapy 6 week prior inclusion visit , irrespective treatment prescribed Patients whose first biologic therapy give part clinical trial study rheumatoid arthritis ( RA ) treatment Patients receive receive experimental DMARDs part clinical trial study RA treatment last 12 month Patients whose first biologic rituximab , abatacept anakinra . Patients receive biologic therapy 6 week prior inclusion visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>